Login to Your Account



Financings Roundup

With CDS Drug Back in House, Targacept Prices $75M Offering

By Jennifer Boggs


Monday, May 23, 2011
About two weeks after AstraZeneca plc passed on an option for TC-5619, Targacept Inc. priced a $75 million public offering to move forward with the alpha7 neuronic nicotinic receptor-targeting drug on its own, with plans to launch a Phase IIb study in cognitive dysfunction in schizophrenia (CDS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription